Incretin Trials Often Exceed Muscle-Loss Benchmarks - Summary - MDSpire
From the Journals
Conference News

Incretin Trials Often Exceed Muscle-Loss Benchmarks

Systematic review finds muscle-related losses frequently surpass expected thresholds during weight loss, though clinical impact remains unclear

Share

A systematic review led by Dr. John A. Batsis from the University of North Carolina evaluated the impact of incretin-based therapies on muscle-related losses in 36 randomized controlled trials. Findings revealed that about two-thirds of these therapies caused muscle-related losses exceeding benchmarks. The review suggests that muscle loss is linked to the magnitude of weight loss rather than drug type and emphasizes the need for objective physical function assessments. The results will be presented at the 2026 American College of Physicians meeting.

Original Source(s)

Incretin Trials Often Exceed Muscle-Loss Benchmarks

  • by Kerri Miller

  • April 17, 2026

Related Content

ACP Updates Breast Cancer Screening Guidance

Biennial mammography recommended for ages 50 to 74 years, with shared decision-making outside that range.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

FURL vs Mini-PCNL in 2 to 3 cm Stones

Review reports comparable stone-free rates with suction-assisted ureteroscopy